Trastuzumab monotherapy or combinations of trastuzumab with carboplatin or weekly paclitaxel or lapatinib as single agents have been previously reported in patients with recurrent ERBB2-amplified or overexpressing recurrent mucinous ovarian carcinomas but responses in all these cases were relatively short in duration (McAlpine et al., 2009, Jain et al., 2012). The gene discussed is ERBB2; the disease is ovarian mucinous adenocarcinoma.